March 29, 2020

Biologics Market is estimated to grow with a CAGR of 9.5% during the forecast period from 2018 to 2026

The latest market report published by Credence Research, Inc. “Biologics Market – Growth, Future Prospects, and Competitive Analysis, 2018 -2026”, the biologics market was valued at US$ 254.9 billion in 2017 and is expected to reach US$ 580.5 billion by 2026 for a CAGR of 9.5 per cent during the 2018-2026 forecast period.

Market Insights

The global market for biologics shows remunerative growth during the forecast period from 2018 to 2026 due to the presence of around 800 biologics in the pipeline. The growth attributed is due to the continuous expansion of the product portfolio, with increasing demand for biologics worldwide. Rising prevalence of chronic diseases, continuous research and development activities and continuous investment in biologics contribute to overall market growth. According to the World Health Organization (WHO), by 2020 chronic diseases account for 75% of global deaths.  Cancer, autoimmune diseases and diabetes account for more than 60% of the overall market in biologics. Approximately 50 percent of the new molecular entities approved by the FDA were biologics in 2016. Continuous development of cellular and gene therapy further catalyzes the market due to its high efficacy and therapeutic outcome. CAR-T cell therapies are the latest FDA approved treatments for oncology indications.

Browse Full Report Originally Published by Credence Research at

Therapeutic expansion of biologics across indications such as asthma, allergic conditions, dyslipidemia and other non-traditional diseases attributed to the expected growth. However, the accelerated expansion of biosimilars has a negative impact on the overall growth of the market in biologics. The cost-effectiveness of biosimilars with similar efficacy would increase demand in developing countries. Biologics approved in the U.S. include longer patent protection compared to those approved in Europe. In addition, EMA has lower biosimilar policies compared to the US FDA, which means that North America has a larger market share than Europe and will remain dominant throughout the forecast period. The increasing prevalence of cancer, autoimmune diseases and diabetes, the presence of leading market players and ongoing research activities are driving the North American market. Asia Pacific is the fastest-growing CAGR double-digit market accounting in the forecast period. The expansion of international players in developing countries contributes to the growth of the biologics market in the region. Novartis AG wishes to launch its FDA-approved Kymriah treatment in Japan. However, discussions on treatment pricing in Japan are still under negotiation with the Ministry of Health and Labor and Welfare (MHLW).

Biologics entering the market contest with similar indications and with more or less similar mechanism of action. Biologics market is thus highly competitive comprising established and leading market players such as Abbvie, Inc., Amgen, Inc., AstraZeneca Plc., Celgene Corporation, Janssen Pharmaceuticals, Inc., Merck & Co. Inc., Novartis AG, Pfizer, Inc., Roche Holding AG, Sanofi S.A and Takeda Pharmaceutical Co., Ltd.

Key Market Movements:

  • Globally, biologics market continues to witness a lucrative growth with a CAGR of 9.5% for the period from 2018 to 2026
  • Presence of an extensive product portfolio and above 800 pipeline molecules, contributed to the overall growth of the market
  • Among all the products available, recombinant therapeutic proteins maintains dominancy comprehending larger market share during the period from 2016 to 2026
  • The introduction of new cellular and gene therapy namely CAR-T cell provides better therapeutic outcome. Furthermore, research activities in this area contributes to the overall market growth during the forecast period.

Access Free Sample Copy of Research Report:

[Note: Our Free Complimentary Sample Report Accommodate a Brief Introduction To The Synopsis, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology are also Included]

Report Scope by Segments

Product Segment (2016–2026; US$ Bn)

  • Recombinant Therapeutic Proteins
    • Monoclonal Antibodies
    • Hormones
    • Cytokines
    • Enzymes
  • Blood & Blood components
  • Cellular & Gene Therapy
  • Vaccines

Disease Segment (2016–2026; US$ Bn)

  • Oncology
    • Breast Cancer
    • Leukemia
    • Ovarian Cancer\
    • Non-Hodgkin Lymphoma
    • Prostate Cancer
    • Colorectal Cancer
    • Others (Bladder Cancer, Lung Cancer, etc.)
  • Autoimmune diseases
    • Systemic Sclerosis
    • Crohn’s Disease
    • Rheumatoid arthritis
    • Systemic Lupus Erythematous
    • Others (Sjogren’s syndrome, multiple sclerosis, pernicious anemia, etc.)
  • Diabetes
  • Infectious diseases
  • Others (cardiovascular diseases, ophthalmic conditions, dermatological diseases, etc.)

By Geography Segment

  • North America (the U.S., Rest of North America)
  • Europe (U.K., Germany, France, Rest of Europe)
  • Asia Pacific (China, Japan, India, Rest of Asia Pacific)
  • Rest of World (Middle East & Africa (MEA), Latin America)

Access Free Sample Copy of Research Report:

Leave a Reply

Your email address will not be published. Required fields are marked *